On February 1, 2023 Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient’s body, reported that its President and Chief Scientific Officer, Anish Suri, Ph.D., will participate in two scientific conferences this February, the Immuno-Oncology 360o Summit, taking place February 7-10 in New York, NY, and the Federation of American Societies for Experimental Biology (FASEB) Catalyst Conference, taking place virtually February 8-9, 2023 (Press release, Cue Biopharma, FEB 1, 2023, View Source [SID1234626721]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr. Suri will present an overview of Cue Biopharma’s Immuno-STAT (Selective Targeting and Alteration of T cells) platform and interleukin 2 (IL-2)-based CUE-100 series of biologics designed to enable selective targeting of IL-2 to tumor-specific T cells.
Presentation Details
Immuno-Oncology 360o
Presentation title: Development, Validation and Application of TCR-selective Engagers for In Vivo Modulation and Persistence of Cell Therapy Products in IO
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Session: Track A: Novel Engineered Cell Therapies and Concepts
Date and time: February 7, 2023, 4:25 – 4:40 p.m. ET
FASEB Catalyst Conference
Presentation title: Immuno-STATs: TCR-selective Engagers of Tumor-specific T Cells
Presenter: Anish Suri, Ph.D., president and chief scientific officer, Cue Biopharma
Date and time: February 9, 2023, 2:00 – 2:30 p.m. ET